The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 17, 2019
Filed:
Jun. 03, 2015
Applicant:
Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);
Inventors:
S. Ananth Karumanchi, Chestnut Hill, MA (US);
Vikas P. Sukhatme, Newton, MA (US);
Assignee:
Beth Israel Deaconess Medical Center, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 38/18 (2006.01); A61K 31/4439 (2006.01); A61K 31/455 (2006.01); A61K 31/513 (2006.01); A61K 31/522 (2006.01); A61K 38/22 (2006.01); C07K 16/28 (2006.01); G01N 33/68 (2006.01); A61K 45/06 (2006.01); C07K 14/495 (2006.01); G01N 33/74 (2006.01);
U.S. Cl.
CPC ...
A61K 38/1841 (2013.01); A61K 31/4439 (2013.01); A61K 31/455 (2013.01); A61K 31/513 (2013.01); A61K 31/522 (2013.01); A61K 38/1866 (2013.01); A61K 38/1875 (2013.01); A61K 38/1891 (2013.01); A61K 38/22 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 14/495 (2013.01); C07K 16/2863 (2013.01); C07K 16/2896 (2013.01); G01N 33/689 (2013.01); G01N 33/74 (2013.01); G01N 2333/71 (2013.01); G01N 2500/00 (2013.01); G01N 2800/368 (2013.01); G01N 2800/60 (2013.01); Y10T 436/143333 (2015.01);
Abstract
Disclosed herein are methods for diagnosing a pregnancy related hypertensive disorder or a predisposition to a pregnancy related hypertensive disorder by measuring the level or biological activity of soluble endoglin. Also disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that alter soluble endoglin levels or biological activity.